CANCER

Attacking Cancer with
Immunotherapies
Jefferson scientists and clinicians continue to
advance new approaches for cancer therapies. Two
potential immune-prompting treatments—one for
solid tumors and advanced non-small-cell lung
carcinoma, and a second for recurrent gastrointestinal
tumors—entered clinical trials in fall 2020.

as chemotherapy.” Dr. Snook led the basic and
translational research with Scott Waldman, MD, PhD,
the Samuel M.V. Hamilton Professor of Medicine
and chair of pharmacology and experimental
therapeutics. Babar Bashir, MD, assistant professor of
medical oncology, leads the clinical trial operation.

The first drug is based on multi-functional immunorecruitment protein based on a fusion protein
platform developed by Mark Tykocinski, MD,
Jefferson provost and Anthony F. and Gertrude M.
DePalma Dean of Sidney Kimmel Medical College.
Created through the chimerization of proteins with
carefully selected characteristics, the treatment is
designed to have a two-part action: first, disabling
cancer cells’ ability to camouflage themselves from
the immune system; then, stimulating proliferation
of T-cells that attack the tumor cells. The current
Phase I/II multi-center clinical trial is evaluating
the drug alone and in combination therapy with
an existing PD-L1-blocking checkpoint inhibitor.

As a vector for prompting the immune system, the
vaccine uses a modified version of the common
adenovirus that incorporates the spike protein
of a rare adenovirus serotype. Having proven the

“It is exciting to see this novel platform moving
forward into clinical development for the
benefit of cancer patients," Dr. Tykocinski says.
“Its potential as both a stand-alone therapeutic
and one used in combination with existing
drugs is enormous. The same goes for the
pipeline of next-generation immunotherapeutic
fusion proteins we are now advancing.”
The second drug undergoing trials targets a
molecule found throughout the small intestine
and colon—guanylyl cyclase C (GUCY2C)—that
continues to be expressed when the cells become
malignant. The drug acts like a vaccine, inducing
the patient’s immune system to seek out and kill
colon cancer cells expressing GUCY2C. “However,
this is not designed to prevent initial development
of the cancer,” explains Adam Snook, PhD, assistant
professor of pharmacology and experimental
therapeutics. “It is designed to prevent cancer
from returning, and is being given after a patient
has surgery and other standard therapies, such
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Our long-term objective is to
add this vaccine strategy to the
toolkit of therapies for a range
of gastrointestinal cancers that
together account for about 20
percent of all cancer death.”
Adam Snook, PhD

vaccine’s safety and efficacy in mouse colon cancer
models, the current Phase IIa clinical trial’s initial
aim is to demonstrate that the drug is capable
of safely inducing significant immune responses
in colon cancer patients. In addition, because
GUCY2C has recently been discovered in gastric,
esophageal and pancreatic cancers—which also
have high recurrence rates—the trial is enrolling
patients with those malignancies. “Our long-term
objective is to add this vaccine strategy to the
toolkit of therapies for a range of gastrointestinal
cancers that together account for about 20
percent of all cancer deaths,” Dr. Snook says. 
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